Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:JUNO

Juno Therapeutics (JUNO) Stock Price, News & Analysis

Juno Therapeutics logo

About Juno Therapeutics Stock (NASDAQ:JUNO)

Key Stats

Today's Range
$86.96
$86.96
50-Day Range
$86.96
$86.96
52-Week Range
$19.62
$87.01
Volume
2 shs
Average Volume
5.48 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Its product candidates JCAR017, JCAR014, and JCAR015, as well as an additional early stage product candidate incorporating a fully human binding domain, leverage CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. Its CAR product candidate JCAR018 targets CD22, a different protein commonly expressed on the surface of B cell leukemias and lymphomas. Its MUC-16 directed product candidate is an armored CAR that secretes the cytokine interleukin 12 (IL-12), which may help to overcome the inhibitory effects that the tumor microenvironment can have on T cell activity.

Receive JUNO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Juno Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

JUNO Stock News Headlines

Shape Therapeutics CEO departs, interim named
625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
See More Headlines

JUNO Stock Analysis - Frequently Asked Questions

Juno Therapeutics Inc (NASDAQ:JUNO) issued its quarterly earnings results on Wednesday, November, 1st. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, topping analysts' consensus estimates of ($0.80) by $0.07. The company's revenue for the quarter was up 115.4% compared to the same quarter last year.

Juno Therapeutics (JUNO) raised $153 million in an IPO on Friday, December 19th 2014. The company issued 9,300,000 shares at a price of $15.00-$18.00 per share. Morgan Stanley, J.P. Morgan and Goldman Sachs served as the underwriters for the IPO and Leerink Partners was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Juno Therapeutics investors own include Bristol-Myers Squibb (BMY), (KITE) (KITE), bluebird bio (BLUE), Gilead Sciences (GILD), Meta Platforms (META), Puma Biotechnology (PBYI) and BioMarin Pharmaceutical (BMRN).

Company Calendar

Last Earnings
11/01/2017
Today
11/06/2024

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:JUNO
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Optionable
Beta
N/A
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:JUNO) was last updated on 11/6/2024 by MarketBeat.com Staff
From Our Partners